Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

276
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
276
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer.

Angiogenesis·2026
Same author

Endoglin (CD105) overexpression is associated with an immunosuppressive tumor microenvironment in murine lung cancer models and human lung adenocarcinoma.

Scientific reports·2026
Same author

Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.

Cancer research·2026
Same author

Vascular growth patterns correlate with histological subtypes in human lung adenocarcinoma.

Experimental and molecular pathology·2026
Same author

A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription.

Nature communications·2025
Same author

Integrins as Key Mediators of Metastasis.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 13, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.7K

Vascular Disruption Therapy as a New Strategy for Cancer Treatment.

Jesús Gómez-Escudero1,2, Patricia Berlana-Galán1,2, Elena Guerra-Paes1,2

  • 1Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, 37007 Salamanca, Spain.

International Journal of Molecular Sciences
|October 29, 2025
PubMed
Summary

Vascular disruption therapy targets and destroys established tumor blood vessels. This review explores novel agents, resistance mechanisms, and future applications for improved cancer treatment.

Keywords:
angiogenesistumor vasculaturevascular disruptionvascular disruption agents

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

9.2K

Related Experiment Videos

Last Updated: Jan 13, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.7K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

9.2K

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Tumor growth necessitates a functional blood vessel network for oxygen and nutrient supply.
  • Tumor angiogenesis, the formation of new blood vessels, is crucial for cancer progression.
  • Limitations in anti-angiogenic therapies have prompted research into alternative vascular modulation strategies.

Purpose of the Study:

  • To review vascular disruption agents (VDAs) in cancer therapy.
  • To discuss novel molecules, resistance mechanisms, and clinical status of VDAs.
  • To highlight upcoming challenges and applications of VDAs.

Main Methods:

  • Review of literature on tumor vascularization and therapeutic strategies.
  • Analysis of mechanisms of action for different classes of VDAs.
  • Evaluation of clinical trial data and limitations of current VDAs.

Main Results:

  • Tumor vasculature exhibits unique characteristics compared to normal vessels.
  • VDAs, including microtubule-binding agents and flavonoids, induce endothelial cell apoptosis.
  • Clinical trials show promise but face challenges like resistant cells and hypoxia.

Conclusions:

  • Vascular disruption therapy offers a distinct approach to targeting tumor vasculature.
  • Overcoming resistance and hypoxia are key challenges for enhancing VDA efficacy.
  • Further research into novel VDAs and combination strategies is essential for advancing cancer treatment.